Despite securing two significant long-term commitments from the U.S. Department of Defense, shares in the data analytics firm Palantir experienced a notable decline. The market’s tepid response on Thursday, which saw the stock drop approximately 4% to €128.84, underscores a prevailing concern among investors: the company’s towering valuation.
A Valuation Conundrum
The core issue dampening the positive news appears to be Palantir’s premium price tag. Currently trading at a price-to-sales multiple near 87, the company stands as the most expensive constituent within the S&P 500 index. This metric highlights a stark contrast between its market capitalization of $370 billion and its most recent annual revenue of $4.5 billion. This disparity has amplified skepticism on Wall Street.
Analysts at Jefferies recently downgraded the stock to a “Sell” rating, with strategist Brent Thill calling the valuation “absurdly expensive” and setting a price target of $70. Institutional investor activity has been mixed. While the Czech National Bank increased its stake, company insiders sold off shares worth more than $140 million in the previous quarter.
Securing Long-Term Government Revenue
The defense sector announcements were unequivocally positive from an operational standpoint. The Pentagon has formally elevated Palantir’s “Maven” artificial intelligence system to a “Program of Record” status, cementing its funding within long-term budgetary plans. This designation is a prestigious milestone in defense contracting, guaranteeing sustained revenue for the company’s automated target recognition platform.
Should investors sell immediately? Or is it worth buying Palantir?
Concurrently, details emerged regarding Palantir’s pivotal role in the massive $185 billion “Golden Dome” missile defense shield initiative. The company is tasked with developing the core software that will integrate sensors and weapon systems in real time, with initial tests scheduled for the summer of 2026.
Balancing Defense with Commercial Growth
To justify its high valuation and achieve its ambitious revenue target of $7.2 billion for the current year—a 61% increase—Palantir must demonstrate robust growth beyond its government contracts. Management is focusing heavily on its commercial segment, particularly in the U.S., which is projected to more than double in size.
The company is actively diversifying its revenue streams through strategic civilian expansions. This includes a deepened partnership with the consulting firm Bain & Company and a newly launched pilot project with the UK’s financial regulatory authority to develop anti-money laundering tools. Wedbush analysts, who maintain a bullish $230 price target, point to an expected annual profit growth rate of 47% over the next five years as a key reason for optimism.
Ultimately, while Palantir continues to lock in formidable, long-term government deals, the market’s reaction suggests that investors are currently more preoccupied with the company’s lofty share price than with its contract wins. The pressure is now on Palantir to deliver exceptional commercial growth to bridge the gap between its current financials and its market valuation.
Ad
Palantir Stock: Buy or Sell?! New Palantir Analysis from March 27 delivers the answer:
The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 27.
Palantir: Buy or sell? Read more here...
